Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (5): 8-14.doi: 10.6040/j.issn.1671-7554.0.2021.0273

• Current Advance of Basic and Clinical Medical Virology • Previous Articles     Next Articles

Current status and prospect of viral vaccines research and development

Kai WANG*()   

  1. Department of Hepatology, Qilu Hospital of Shandong University; Institute of Hepatology, Shandong University, Jinan 250012, Shandong, China
  • Received:2021-03-10 Online:2021-05-10 Published:2021-06-01
  • Contact: Kai WANG E-mail:wangdoc876@126.com; wangdoc2010@163.com

RichHTML

594

PDF (PC)

2350

Abstract:

Virus infection can cause several diseases in human. In the past decades, outbreaks and epidemics of respiratory infectious diseases caused by coronary viruses, especially coronavirus disease 2019 (COVID-19), have become serious health hazards and posed huge challenges to public health. The development and application of viral vaccines have been an important means to counteract the spread of viruses. Historically, poliovirus and hepatitis B virus vaccines have successfully suppressed the transmission of diseases and provided a model for the development of vaccines. Recently, the emergence of novel technologies and platforms such as recombinant viral vector and mRNA vaccine has provided new approaches to the development of vaccines against emerging infectious diseases including COVID-19. This paper reviews the current situation and progress of platforms, summarizes problems to be solved, and forecasts the directions of viral vaccines development.

Key words: Viral vaccine, Coronavirus, Recombinant viral vector, mRNA vaccine, Antibody-dependent enhancement

CLC Number: 

  • R186
1 Katz IT , Weintraub R , Bekker LG , et al. From vaccine nationalism to vaccine equity-finding a path forward[J]. Lancet, 2021, 384 (14): 1281- 1283.
2 Ansariniya H , Seifati SM , Zaker E , et al. Comparison of immune response between SARS, MERS, and COVID-19 infection, perspective on vaccine design and development[J]. Biomed Res Int, 2021, 2021, 8870425.
doi: 10.1155/2021/8870425
3 Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members . Operation Warp Speed: implications for global vaccine security[J]. Lancet Glob Health, 2021, S2214-109X (21): 00140- 00146.
doi: 10.1016/S2214-109X(21)00140-6
4 Alfaro-Murillo JA , Avila-Aguero ML , Fitzpatrick MC , et al. The case for replacing live oral polio vaccine with inactivated vaccine in the Americas[J]. Lancet, 2020, 395 (10230): 1163- 1166.
doi: 10.1016/S0140-6736(20)30213-0
5 Bravo C , Mege L , Vigne C , et al. Clinical experience with the inactivated hepatitis a vaccine, Avaxim 80U Pediatric[J]. Expert Rev Vaccines, 2019, 18 (3): 209- 223.
doi: 10.1080/14760584.2019.1580578
6 Mao QY , Wang Y , Bian L , et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD)[J]. Expert Rev Vaccines, 2016, 15 (5): 599- 606.
doi: 10.1586/14760584.2016.1138862
7 Wood JM , Robertson JS . From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza[J]. Nat Rev Microbiol, 2004, 2 (10): 842- 847.
doi: 10.1038/nrmicro979
8 Tahir Ul Qamar M , Saleem S , Ashfaa UA , et al. Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: an immune-informatics study[J]. J Transl Med, 2019, 17 (1): 362.
doi: 10.1186/s12967-019-2116-8
9 Watanabe Y , Allen JD , Wrapp D , et al. Site-specific glycan analysis of the SARS-CoV-2 spike[J]. Science, 2020, 369 (6501): 330- 333.
doi: 10.1126/science.abb9983
10 Jeyanathan M , Afkhami S , Smaill F , et al. Immunological considerations for COVID-19 vaccine strategies[J]. Nat Rev Immunol, 2020, 20 (10): 615- 632.
doi: 10.1038/s41577-020-00434-6
11 Lamb YN . Cell-based quadrivalent inactivated influenza virus vaccine (FlucelvaxTetra/Flucelvax Quadrivalent): a review in the prevention of influenza[J]. Drugs, 2019, 79 (12): 1337- 1348.
doi: 10.1007/s40265-019-01176-z
12 Izurieta HS , Chillarige Y , Kelman J , et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the united states, 2017-2018[J]. J Infect Dis, 2019, 220 (8): 1255- 1264.
doi: 10.1093/infdis/jiy716
13 Wang H , Zhang Y , Huang B , et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2[J]. Cell, 2020, 182 (3): 713- 721.
doi: 10.1016/j.cell.2020.06.008
14 Gao Q , Bao L , Mao H , et al. Development of an inactivated vaccine candidate for SARS-CoV-2[J]. Science, 2020, 369 (6499): 77- 81.
doi: 10.1126/science.abc1932
15 Jimenez-Guardeno JM , Regla-Nava JA , Nieto-Torres JL , et al. Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine[J]. PLoS Pathog, 2015, 11 (10): e1005215.
doi: 10.1371/journal.ppat.1005215
16 Mueller S , Stauft CB , Kalkeri R , et al. A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates[J]. Vaccine, 2020, 38 (14): 2943- 2948.
doi: 10.1016/j.vaccine.2020.02.056
17 Bolles M , Deming D , Long K , et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge[J]. J Virol, 2011, 85 (23): 12201- 12215.
doi: 10.1128/JVI.06048-11
18 Diamond MS , Pierson TC . The challenges of vaccine development against a new virus during a pandemic[J]. Cell Host Microbe, 2020, 27 (5): 699- 703.
doi: 10.1016/j.chom.2020.04.021
19 Oscherwitz J . The promise and challenge of epitope-focused vaccines[J]. Hum Vaccin Immunother, 2016, 12 (8): 2113- 2116.
doi: 10.1080/21645515.2016.1160977
20 Liang JG , Su D , Song TZ , et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates[J]. Nat Commun, 2021, 12 (1): 1346.
doi: 10.1038/s41467-021-21634-1
21 Yang J , Wang W , Chen Z , et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity[J]. Nature, 2020, 586 (7830): 572- 577.
doi: 10.1038/s41586-020-2599-8
22 Nooraei S , Bahrulolum H , Hoseini ZS , et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers[J]. J Nanobiotechnology, 2021, 19 (1): 59.
doi: 10.1186/s12951-021-00806-7
23 Qian C , Liu X , Xu Q , et al. Recent progress on the versatility of virus-like particles[J]. Vaccines (Basel), 2020, 8 (1): 139.
doi: 10.3390/vaccines8010139
24 Li Z , Wang D , Gu Y , et al. Crystal structures of two immune complexes identify determinants for viral infectivity and type-specific neutralization of human papillomavirus[J]. mBio, 2017, 8 (5): e00787- 17.
doi: 10.1128/mBio.00787-17
25 Lokugamage KG , Yoshikawa-Iwata N , Ito N , et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV[J]. Vaccine, 2008, 26 (6): 797- 808.
doi: 10.1016/j.vaccine.2007.11.092
26 Lu X , Chen Y , Bai B , et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice[J]. Immunology, 2007, 122 (4): 496- 502.
doi: 10.1111/j.1365-2567.2007.02676.x
27 Naskalska A , Dabrowska A , Nowak P , et al. Novel coronavirus-like particles targeting cells lining the respiratory tract[J]. PLoS One, 2018, 13 (9): e0203489.
doi: 10.1371/journal.pone.0203489
28 Donaldson B , Lateef Z , Walker GF , et al. Virus-like particle vaccines: immunology and formulation for clinical translation[J]. Expert Rev Vaccines, 2018, 17 (9): 833- 849.
doi: 10.1080/14760584.2018.1516552
29 Humphreys IR , Sebastian S . Novel viral vectors in infectious diseases[J]. Immunology, 2018, 153 (1): 1- 9.
doi: 10.1111/imm.12829
30 Afkhami S , Yao Y , Xing Z . Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens[J]. Mol Ther Methods Clin Dev, 2016, 3, 16030.
doi: 10.1038/mtm.2016.30
31 Zhu FC , Hou LH , Li JX , et al. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial[J]. Lancet, 2015, 385 (9984): 2272- 2279.
doi: 10.1016/S0140-6736(15)60553-0
32 Zhu FC , Li YH , Guan XH , et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial[J]. Lancet, 2020, 395 (10240): 1845- 1854.
doi: 10.1016/S0140-6736(20)31208-3
33 Zhu FC , Guan XH , Li YH , et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2020, 396 (10249): 479- 488.
doi: 10.1016/S0140-6736(20)31605-6
34 Henao-Restrepo AM , Longini IM , Egger M , et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial[J]. Lancet, 2015, 386 (9996): 857- 866.
doi: 10.1016/S0140-6736(15)61117-5
35 Pardi N , Hogan MJ , Porter FW , et al. mRNA vaccines-a new era in vaccinology[J]. Nat Rev Drug Discov, 2018, 17 (4): 261- 279.
doi: 10.1038/nrd.2017.243
36 Chagla Z . The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose[J]. Ann Intern Med, 2021, 174 (2): JC15.
doi: 10.7326/ACPJ202102160-015
37 Walsh EE , FrenckJr RW , Falsey AR , et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates[J]. N Engl J Med, 2020, 383 (25): 2439- 2450.
doi: 10.1056/NEJMoa2027906
38 Pardi N , Parkhouse K , Kirkpatrick E , et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies[J]. Nat Commun, 2018, 9 (1): 3361.
doi: 10.1038/s41467-018-05482-0
39 Feldman RA , Fuhr R , Smolenov I , et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials[J]. Vaccine, 2019, 37 (25): 3326- 3334.
doi: 10.1016/j.vaccine.2019.04.074
40 Shaw CA , Ciarlet M , Cooper BW , et al. The path to an RSV vaccine[J]. Curr Opin Virol, 2013, 3 (3): 332- 342.
doi: 10.1016/j.coviro.2013.05.003
41 Sheerin D , Openshaw PJ , Pollard AJ . Issues in vaccinology: Present challenges and future directions[J]. Eur J Immunol, 2017, 47 (12): 2017- 2025.
doi: 10.1002/eji.201746942
42 Lee WS , Wheatley AK , Kent SJ , et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies[J]. Nat Microbiol, 2020, 5 (10): 1185- 1191.
doi: 10.1038/s41564-020-00789-5
43 Morrone SR , Lok SM . Structural perspectives of antibody-dependent enhancement of infection of dengue virus[J]. Curr Opin Virol, 2019, 36, 1- 8.
doi: 10.1016/j.coviro.2019.02.002
44 Boyaka PN . Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems[J]. J Immunol, 2017, 199 (1): 9- 16.
doi: 10.4049/jimmunol.1601775
45 Woodrow KA , Bennett KM , Lo DD . Mucosal vaccine design and delivery[J]. Annu Rev Biomed Eng, 2012, 14, 17- 46.
doi: 10.1146/annurev-bioeng-071811-150054
46 Miquel-Clopes A , Bentley EG , Stewart JP , et al. Mucosal vaccines and technology[J]. Clin Exp Immunol, 2019, 196 (2): 205- 214.
47 Coffman RL , Sher A , Seder RA . Vaccine adjuvants: putting innate immunity to work[J]. Immunity, 2010, 33 (4): 492- 503.
doi: 10.1016/j.immuni.2010.10.002
[1] Xi ZHOU,Muhan HUANG,Yujie REN,Yang QIU. SARS-CoV-2 infection, innate immunity and inflammatory response [J]. Journal of Shandong University (Health Sciences), 2021, 59(5): 15-21.
[2] DONG Hongjie, ZHANG Junmei, WANG Shuai, WANG Hongwei, ZHANG KundiHU Wei, XIE Xiaohong, XIE Shiling, GU Lichuan. Research on mixed sample test for SARS-CoV-2 [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 1-5.
[3] YU Ying, ZHANG Gong, LIU Jing, YAN Shitong, HAN Tao, HUANG Hailiang. Potential mechanism of Astragalus membranaceus in the prevention of COVID-19 based on network pharmacology and molecular docking [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 6-16.
[4] CAO Aihua, DUAN Chunhong, QIU Bingping, LU Ling, LI Keliang, LIU Xuegong, ZHOU Zhiyuan, SUN Jianhua, JU Xiuli. Epidemiological and clinical characteristics of children infected with SARS-CoV-2 in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2020, 58(6): 34-40.
[5] CHENG Zhaoping, DUAN Yanhua, YAO Jinkun, LI Yan, GU Hui, YUAN Xianshun, LIU Bin, BI Wanli, SONG Zhaoliang, NIE Pei, CHEN Yueqin, SUN Zhanguo, LIU Shanping, WANG Luguang, TANG Zhongren, WEI Xianglei, DONG Liang, WANG Chunting, WANG Ximing. Chest CT features of 105 patients with COVID-19: a multicenter retrospective study in Shandong Province [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 38-45.
[6] LI Xiaofei, LIU Guiming, LI Wanlan, LYU Songqin, NIE Lei, ZHANG Juan, XU Liping, LU Nihong. Application value of chemiluminescent immunoassay in the detection of 2019-nCoV antibodies [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 46-50.
[7] YUAN Yonggui, LI Lei, SHEN Zhongxia, CHEN Gang, WU Yigao, YUE Yingying. Prevention and control strategy for the diagnosis and treatment of psychiatric disorders during the epidemic of coronavirus disease 2019 [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 1-6.
[8] CHANG Caiyun, YU Qiuyan, ZHAO Xiaodong, WANG Fang, LI Wei, RUAN Shiman, GENG Xingyi. Epidemiological characteristics of the first COVID-19 case and related family cluster outbreaks in Jinan City [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 7-11.
[9] YANG Li, LI Zhan, LIU Xiaoxue, JIAO Haitao, ZHOU Lin, LIU Qingjie, LIU Tiecheng, GENG Xingyi. Analysis and evaluation of the isolation medicine observation for close contacts of New Coronavirus Pneumonia in Jinan City [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 12-16.
[10] QIAO Yu, CUI Liangliang, LI Shuai, WANG Feng, RUAN Shiman, JING Yiming, LIU Chong. Research and development of intelligent question answering robot system: a case study of its application in response to COVID-19 epidemic in Jinan City [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 17-22.
[11] LI Xinrui, GENG Xingyi, ZHAO Xiaodong, LIU Lanzheng, WANG Weiru, CUI Liangliang, LI Zhan, CHANG Caiyun, RUAN Shiman. A comprehensive analysis of 47 COVID-19 cases in Jinan City [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 23-27.
[12] LI Xinrui, GENG Xingyi, WANG Weiru, ZHAO Xiaodong, LIU Lanzheng, ZHANG Xiaofei, LÜ Cuixia, CHANG Caiyun, LI Zhan, CUI Liangliang, RUAN Shiman. Consideration about cluster epidemic of 37 COVID-19 cases [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 32-40.
[13] YANG Liu, LI Zhan, XU Huaru, CHANG Caiyun, LIU Zhong, LI Chuanbin, SUN Zhan, JING Rui, LIU Tiecheng, GENG Xingyi, ZHOU Jingwen. Epidemiological and clinical characteristics of 10 children with coronavirus disease(COVID-19)in Jinan City [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 36-39.
[14] LIU Zhong, ZHAO Mengjiao, YANG Guoliang, ZHAO Huailong, WANG Linlin, CHANG Caiyun, GENG Xingyi. Investigation of a COVID-19 case with unknown cause and its close contacts [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 49-53.
[15] WANG Weiru, LI Xinrui, WANG Fang, ZHAO Xiaodong, YU Qiuyan, YANG Guoliang, LI Zhan, CHANG Caiyun, ZHAO Mengjiao, LIU Xiaoxue, LI Chuanbin, SUN Zhan, GENG Xingyi. Analysis of a family cluster outbreak of coronavirus disease 2019 in Jinan City [J]. Journal of Shandong University (Health Sciences), 2020, 58(4): 54-57.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd